Tucatinib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 270 publications
Real-World Effectiveness and Safety of Tucatinib, Trastuzumab, and Capecitabine in HER2-Positive Advanced Breast Cancer: A Multicenter Portuguese Study.
Journal: European journal of breast health
Published: June 19, 2026
Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies.
Journal: Expert opinion on drug safety
Published: May 04, 2026
Identification of small-molecule inhibitors targeting HER2 for breast cancer therapy using structure-based virtual screening, ADMET profiling, and molecular dynamics simulations.
Journal: Cellular and molecular biology (Noisy-le-Grand, France)
Published: March 16, 2026
Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer.
Journal: Scientific reports
Published: March 10, 2026
Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: March 06, 2026
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; pembrolizumab for head and neck cancer, tucatinib for breast cancer, and trametinib for ovarian cancer.
Journal: International journal of clinical oncology
Published: February 28, 2026
Quantitation of Tucatinib, a Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC-ESI-MS/MS: Application to a Pharmacokinetic Study in Mice.
Journal: Biomedical chromatography : BMC
Published: February 24, 2026
Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib.
Journal: Journal of clinical medicine
Published: February 04, 2026
Repurposing Lapatinib and Tucatinib as Dual Inhibitors of Bcl-2 and TYMS in Breast Cancer: Insights from Transcriptomic, Computational and Cellular Assays.
Journal: Applied biochemistry and biotechnology
Published: February 04, 2026
Post-Chemotherapy Antibody-Based Continuation and Maintenance Strategies in HER2-Positive Metastatic Breast Cancer: A Translational Narrative Review.
Journal: Antibodies (Basel, Switzerland)
Published: January 31, 2026
Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2-positive metastatic colorectal cancer.
Journal: Journal of comparative effectiveness research
Published: January 28, 2026
Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices.
Journal: Breast cancer (Dove Medical Press)
Published: January 27, 2026
Last Updated: 06/30/2026